Pharmaceuticals
Pharmaceuticals
We support pharmaceutical firms and medical affairs sections in medical device companies in Japan, working to develop real-world evidence. We draft research design to advise on the selection of appropriate real-world data, draft forms for protocol/ethics committees, analyze data, and develop materials for academic conferences. We develop, identify, select, propose, and assess the most appropriate analytic methods for given research questions.
Healthcare solutions
- Real World Data (RWD) Utilization in Health Economics & Outcomes Research (HEOR)
- Systematic Review, Meta-analysis, and Network Meta-analysis
- Real World Evidence Generation
- Social Simulation, Healthcare Insurance Reform, Agent-Based Model
- Introduction of Potential Value Accounting as a Management Compass
Real World Data (RWD) Utilization in Health Economics & Outcomes Research (HEOR)
In the field of Health Economics & Outcomes Research (HEOR), we have conducted numerous projects with various clients, presenting outcomes in peer-reviewed academic journals or conferences such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Our expertise lies particularly in research within the HEOR domain using Real World Data (RWD). Unlike randomized controlled trials (RCTs) that provide some internal validity through random allocation, comparing outcomes within RWD requires careful adjustment for confounding factors. Failure to adjust for confounding factors can lead to natural disparities in outcomes, such as when prioritized treatment is administered to severe cases, resulting in worse outcomes in the treatment group compared to the non-treatment group. We employ various methods of confounding adjustment to select the most suitable for each research question and execute accordingly.
One method utilized, as seen in Koretsune (2018), is Doubly Robust Estimation, which combines propensity score-based inverse probability weighting with regression models to ensure correctness if either method is accurate. Yamada (2018) and Yamada (2020) utilized machine learning techniques to develop outcome prediction models, adjusting for confounding factors using the predicted values.
The reason why Milliman, a consulting firm specializing in actuarial science, conducts HEOR research is rooted in actuaries traditionally being experts in confounding adjustment. Actuaries are indispensable in modern life insurance for assessing individual risk, which forms the basis of confounding adjustment, as indicated in Wikipedia's definition of actuaries.
It is acknowledged that complete confounding adjustment is not always achievable. Particularly, when crucial confounding factors with significant impacts on outcomes are absent from observed data, issues arise. For example, certain disease severities commonly used in clinical settings may not be directly documented in claims data. However, if information to replicate such severity levels is available, some level of confounding adjustment remains feasible.
Kawachi (2022) attempted to reproduce the commonly used Expanded Disability Status Scale (EDSS) for multiple sclerosis severity from claims data, though EDSS data are not directly available in claims data and extracting it from electronic medical records entails significant effort. However, by creating an index combining indicators correlated with severity using principal component analysis (PCA), confounding adjustment becomes possible, enabling comparative studies.
Another method, High-dimensional Propensity Score Adjustment, utilizes all observed information for adjustment when indirect information on confounding factors is presumed to be included. Though not widely used in publicized research, we have experience employing this method in several projects.
When crucial confounding factors are absent and cannot be replicated with all observed factors, outcomes of comparative analyses using RWD may lack robustness. In such cases, we strive to enhance credibility by seeking opinions from internal and external medical experts on the importance of confounding factors, comparing outcomes through various methods of confounding adjustment, and replicating results of existing RCTs on similar themes within RWD.
Research
| 発表形式 | スポンサー | 疾病 | 発行年月 | 内容 |
|---|---|---|---|---|
| 論文 | ノバルティスファーマ | 眼科領域の治療実態 | 2024年4月1日 | Fumi Gomi, Ryo Kawasaki, Yuichiro Ogura, Kosuke Iwasaki, Tomomi Takeshima, Masafumi Yamabe, Kota Imai. Patterns of anti-vascular endothelial growth factor treatment for chorioretinal vascular diseases: Analysis of a nationwide claims database in Japan. Annals of Clinical Epidemiology 2024;6(2):42–50 |
| プレゼン資料 | なし | なし | 2023年12月 | 民間がん保険の被保険利益について – QOLファイナンスの可能性. 11回QOL-PRO研究会学術集会. 2023年12月23日一般演題2 15:50～17:00 |
| プレゼン資料 | なし | なし | 2023年11月 | 岩崎宏介. 日本のレセプトデータにおける傷病データの問題点：データ解析実務者の立場から. 日本薬剤疫学会第28回学術総会. 2023年11月18日 |
| ポスター | なし | 不眠症 | 2023年11月 | 武島智美、岩崎宏介. レセプトデータ解析による不眠症患者に対するオンライン診療の実態 日本薬剤疫学会第28回学術総会. 2023年11月17日 |
| ポスター | 東京大学 | 心臓弁膜症 | 2023年11月 | Igarashi A, Iwasaki K, Takeshima T. Prevalence, Incidence, and Patient Characteristics of Valvular Heart Disease Using the National Database of Health Insurance Claims in Japan-ISPOR Europe Copehagen, 13-15 November 2023. |
| ポスター | 塩野義製薬 | 精神障害 | 2023年11月 | Iwasaki K, Ha C, Takeshima T, Sato Y, Hiroi S, Sugiyama T, Terashima G, Hatakama A, Igarashi A. Incidence and Risk Factors for Psychiatric Disorders Across Different Health Insurance Systems in Japan-ISPOR Europe Copenhagen, 13-15 November 2023. |
| ポスター | 塩野義製薬 | 産後鬱？ | 2023年11月 | Iwasaki K, Ha C, Takeshima T, Sato Y, Hiroi S, Hatakama A, Igarashi A. Incidence of postpartum mental and behavioral disorders in Japan-ISPOR Europee 2023 at Copenhagen, 13-15 November 2023. |
| ポスター | 塩野義製薬 | COVID-19 | 2023年11月 | Itsumura N, Kurazono K, Hiroi S, Ha C, Iwasaki K. What Factors Influence the Prescription of Oral Antivirals for COVID-19 in Japan? ̶ a State Transitional Agent-Based Model Analysis - ISPOR Europe 2023 at Copenhagen 09:00 - 11:30, Wednesday, 15 November 2023. |
| ポスター | なし | 2型糖尿病 | 2023年11月 | Nakamura M, Mizoroki K, Iwasaki K, Takeshima T, Ha C, Chida A. Consistency Between Network Meta-Analysis and Real-World Data Analysis: Comparison of Changes in Hemoglobin A1c Levels After Treatment by Oral Antidiabetics in Japanese Patients with Type 2 Diabetes. ISPOR Europe 2023 at Copenhagen 09:00 - 11:30, Wednesday, 15 November 2023. |
| ポスター | なし | 認知症 | 2023年11月 | Ha C, Iwasaki K, Takeshima T, Chida A, Mano T. How Many Patients Diagnosed with Mild Cognitive Impairment Are Willing to Pay for a PET Scan to Receive the Treatment for Alzheimer's Disease in Japan? ISPOR Europe 2023 at Copenhagen 15:30 - 18:30, Monday, 13 November 2023. |
| ポスター | なし | 妊婦に対する降圧剤 | 2023年10月 | Chida A. Iwasaki K. Prescription Status in Japan of Antihypertensive Drugs Contraindicated in Pregnant Women An Analysis Using Real World Data. ACPE 2023, Bengaluru, 26-28 Oct. 2023. |
| ポスター | なし | 脳梗塞 | 2023年10月 | Chida A, Iwasaki K, Ha C. Risk of Postoperative Cerebral Infarction in Patients with Aortic Stricture by Types of Surgeries An Analysis Using Real World Data. ACPE 2023, Bengaluru, 26-28 Oct. 2023. |
| 論文 | 日本新薬 | 貧血 | 2023年10月 | Takeshima T, Yamamoto Y, Iwasaki K, Ha C, Oishi M, Sato A, Sonoyama Y, Honda N, Niida H, Takeda J. Prevalence, treatment status, medical costs, quality of life, and productivity loss in Japanese adult patients with anemia: a real-world database study. J Med Econ. 2023 Jan-Dec;26(1):1386-1397. doi: 10.1080/13696998.2023.2271752. Epub 2023 Oct 28. PMID: 37849298. |
| ポスター | 東京大学、自治医科大学、塩野義製薬 | インフルエンザ | 2023年9月 | Tamura D, Iwasaki K, Sato Y, Yoshida M, Hiroi S, Shimizu E. Test, Diagnosis, and Anti viral Treatment of Influenza in Japan: Analysis of National Database. The 9th European Scientific Working Group on Influenza (ESWI) Conference. Sep 17-20, 2023. |
| 論文 | 塩野義製薬 | COVID-19 | 2023年6月 | Morita I, Kurazono K, Yoshida M, Hiroi S, Iwasaki K, Takeshima T, Ha C, Igarashi A. Preferences and values for government policies on infectious disease outbreaks and epidemics for the Japanese population: a conjoint analysis. J Med Econ. 2023;26(1):793-801. |
| 論文 | 塩野義製薬 | COVID-19 | 2023年6月 | Hosogaya, N., Takazono, T., Kurazono, K. et al. Estimation of Intangible Costs for Factors Associated with Oral Antiviral Drugs for COVID-19 Treatment: A Conjoint Analysis in Japan. Adv Ther (2023). https://doi.org/10.1007/s12325-023-02564-4 |
| 論文 | 塩野義製薬 | 乳癌 | 2023年6月 | Yoshida M, Iwasaki K, Miyashita M, Saeki T, Morioka Y, Hiroi S, Shimizu E. Opioid prescriptions at the point of surgery, bone metastasis, or death among patients with breast cancer in Japanese acute care hospitals: a claims-based, retrospective, longitudinal study. Support Care Cancer. 2023 Jun 2;31(6):369. doi: 10.1007/s00520-023-07805-4. |
| ポスター | DeSCヘルスケア | なし | 2023年5月 | Iwasaki K, Ha C, Takeshima T. Effects of improved health indices on the quality of life and healthcare costs. International Congress of Actuaries, 28 May – 1 June 2023, Sydney |
| ポスター | 塩野義製薬、JMDC, DeSC | 精神疾患 | 2023年5月 | Iwasaki K, Ha C, Takeshima T, Sato Y, Nishi I, Yoshida M, Hiroi S, Sugiyama T, Terashima G, Hatakama A, Igarashi A. Medical Cost and Prevalence of Mental Diseases across Different Health Insurance Systems in Japan. ISPOR 2023 at Boston, 07 May-10 May 2023. |
| ポスター | なし | 貧血 | 2023年5月 | Takeshima T, Iwasaki K. Factors Associated with Anemia Based on an Analysis of National Health and Nutrition Examination Survey Data. Postor session 2 of ISPOR 2023 at Boston. 07 May-10 May, 2023. |
| ポスター | NTT Data | なし | 2023年5月 | Takeshima T, Hasegawa Y, Asami K, Ha C, Iwasaki K. Reproduction of the Control Group in REMDACTA Trial Using the Millennial Medical Record, an Electronic Health Record Database, in Japan. Poster session 1 of ISPOR 2023 at Boston, 07 May-10 May, 2023. |
| 論文 | エドワーズ | 心臓弁膜症 | 2023年5月 | Izumi C, Matsuyama R, Yamabe K, Iwasaki K, Takeshima T, Murphy SME, Teng L, Igarashi A. In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data. Clinicoecon Outcomes Res. 2023;15:349-360 |
| 論文 | 住友ファーマ | 2型糖尿病 | 2023年4月 | Rimei Nishimura, Tomomi Takeshima, Kosuke Iwasaki, Sumiko Aoi. Prescription patterns and therapeutic effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycemic agents. Expert Opin Pharmacother. 2023 Apr 26;1-8. doi: 10.1080/14656566.2023.2206016. |
| 論文 | エドワーズ | 心臓弁膜症 | 2023年3月 | Izumi C, Matsuyama R, Asaoka M, Iwasaki K, Takeshima T, Murphy S, Teng L, Igarashi A. Valvular heart disease in Japan: Characteristics and treatment of patients in acute care hospitals in 2019. J Cardiol. 2023 Mar 22:S0914-5087(23)00055-2. doi: 10.1016/j.jjcc.2023.03.007. Epub ahead of print. PMID: 36963659. |
| その他 | なし | なし | 2023年3月 | 岩崎宏介. 巻頭言. JARIP Bulletin (機関誌) 巻頭言 Vol.6, 2022 No.2 |
| 論文 | なし | アルツハイマー病 | 32023年3月 | 河智世. アルツハイマー病の前兆的な要因について=DｅSＣへルスケア株式会社提供データベースの活用例. JARIP Bulletin (機関誌) 寄稿論文1 Vol.6, 2022 No.2 |
| 論文 | 大塚製薬 | パーキンソン病 | 2023年1月 | Tsuboi, Y, Wada-Isoe, K, Kondo, H, Kojima, Y, Takeshima, T, Iwasaki, K. Differences in Parkinson's disease treatment between neurology and other departments in Japan. Neurol Clin Neurosci. 2023; 00: 1- 11. doi:10.1111/ncn3.12699 (Jan. 26, 2023) |
| 論文 | なし | ピロリ菌 | 2023年1月 | Mizukami K, Sugano K, Takeshima T, Murakami K, Mizukami K, Murakami K, Disease trends after Helicobacter pylori eradication based on Japanese nationwide claims and the health check-up database. World J Gastroenterol 2023; 29(4): 692-705 |
| 論文 | 大塚製薬 | パーキンソン病 | 2023年1月 | Wada-Isoe, K, Tsuboi, Y, Kondo, H, Kojima, Y, Takeshima, T, Iwasaki, K. Non-ergot dopamine agonist therapy for Parkinson's disease in Japan: A claims database analysis. Neurol Clin Neurosci. 2023; 00: 1- 9. |
| 論文 | 日本新薬 | 貧血 | 2023年1月 | Takeshima T, Ha C, Iwasaki K. Estimation of the utilities of attributes of intravenous iron infusion treatment for patients with iron-deficiency anemia: a conjoint analysis in Japan. J Med Econ. 2023 Jan-Dec;26(1):84-94. doi: 10.1080/13696998.2022.2158661. PMID: 36519281. |
| その他 | なし | なし | 2022年11月 | Iwasaki K, Takeshima T, Ha C. Real World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) -European Forum in London Nov. 4, 2022 |
| 論文 | なし | なし | 2022年11月 | 岩崎宏介. 米国のデジタルヘルスビジネスと日本の健康保険者による「予防・重症化予備・健康づくり」のビジネス/ロジックモデル案」. JARIP Bulletin 寄稿論文2 Vol.6, 2022 No1. |
| ポスター | 塩野義製薬 | なし | 2022年11月 | Iwasaki K, Ha C, Takeshima T, Nishi I, Yoshida M, Hiroi S, Sugiyama T, Terashima G, Nakagawa T, Hatakama A, Igarashi A. Medical Cost and Prevalence of Diseases across Different Health Insurance Systems in Japan. Poster Session 3 of ISPOR Europe 2022 at Vienna, Austria. (Nov. 06-09, 2022) |
| ポスター | プリベント | なし | 2022年11月 | Yamamoto K, Iwasaki K, Hagiwara Y, Takeshima T. Effects of Mobile Health-Based Personalized Disease Management Program Intervened by Health Professionals Through a Mobile App and Telephone Interviews in Reducing Medical Costs. ISPOR EUROPE 2022(Nov. 06-09, 2022) |
| ポスター | ボストン・サイエンティフィック | 重症下肢虚血 | 2022年11月 | Takashima K, Ariyaratne T. Takeshima T, Tateyama M, Iwasaki K. Risk Factors for Below-the-Knee Amputation in Japanese Patients with Critical Limb Ischemia Who Underwent Plain Old Balloon Angioplasty Therapy: A Claims Database Analysis. ISPOR EUROPE 2022 (Nov. 06-09, 2022) |
| ポスター | 日本新薬 | 貧血 | 2022年11月 | Iwasaki K, Takeshima T, Tateyama M, Ha C, Takeda J. Utilization of Intravenous Iron Preparations for Iron Deficiency Anemia: A Longitudinal Study Using a Japanese Health Insurance Claims Database with Annual Health Check-Ups in 2018-2021. Poster Session 5 of ISPOR Europe 2022 at Vienna, Austria. (Nov. 06-09, 2022) |
| ポスター | なし | アルツハイマー病 | 2022年11月 | Ha C, Iwasaki K, Takeshima T. Odds Ratio of Each Disease Before Incidence of Alzheimer's Disease - A Case Control Study Using Japanese Health Insurance Claims Data. Poster Session 2 of ISPOR EUROPE 2022 at Vienna, Austria (Nov. 06-09, 2022) |
| ポスター | エーザイ | アルツハイマー病 | 2022年11月 | Igarashi A, Ikeda S. The current status and challenges of value assessment in prevention and treatment for alzheimer's disease dementia in Japan. ISPOR EUROPE 2022 (Nov. 06-09, 2022) |
| 論文 | 塩野義製薬 | 特発性肺線維症 | 2022年9月 | Suda T, Kondoh Y, Hongo Y, Yoshida M, Hiroi S, Iwasaki K, Takeshima T, Homma S. Current treatment status of patients with idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respir Investig. 2022 Sep 16:S2212-5345(22)00116-2. doi: 10.1016/j.resinv.2022.08.004. Epub ahead of print. PMID: 36123241. |
| 論文 | エーザイ | アルツハイマー病 | 2022年8月 | Igarashi A, Ikeda S. Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interview. Expert Rev Pharmacoecon Outcomes Res. 2022 Aug 30. doi: 10.1080/14737167.2022.2118113. Epub ahead of print. PMID: 36039772. |
| その他 | なし | なし | 2022年8月 | 岩崎宏介. 米国のデジタルヘルスビジネスと日本の市町村による予防・重症化予防・健康づくりのロジックモデル案. 2022年8月26日. 神戸リサーチコンプレックス協議会シンポジウム |
| 論文 | 塩野義製薬 | 特発性肺線維症 | 2022年7月 | Homma S, Suda T, Hongo Y, Yoshida M, Hiroi S, Iwasaki K, Takeshima T, Kondoh Y. Incidence and changes in treatment of acute exacerbation of idiopathic pulmonary fibrosis in Japan: A claims-based retrospective study. Respir Investig. 2022 Sep 3:S2212-5345(22)00111-3. doi: 10.1016/j.resinv.2022.07.004. Epub ahead of print. PMID: 36068159. |
| 論文 | ノバルティス | 心不全 | 2022年6月 | Eguchi S, Morita Y, Mitani H, Kanegasaki A, Iwasaki K, Yoshikawa T, Kitagawa H, Oyama N. Burden of Repeated Hospitalizations on Patients with Heart Failure: An Analysis of Administrative and Claims Data in Japan. Drugs Real World Outcomes. 2022 Jun 26. doi: 10.1007/s40801-022-00315-5. Epub ahead of print. PMID: 35753032. |
| 論文 | ノバルティス | 多発性硬化症 | 2022年6月 | Kawachi I, Otaka H, Iwasaki K, Takeshima T, Ueda K. Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis. Neurol Ther. 2022 Jun 17. doi: 10.1007/s40120-022-00374-4. Epub ahead of print. PMID: 35713761. |
| その他 | 塩野義製薬 | 乳がん | 2022年6月 | 本郷良泳、佐伯俊昭、清水央子：日本における乳がん患者に対する オピオイド処方の実態：後向きデータベース研究－第30回日本乳癌学会学術総会（June 09,2022) |
| ポスター | なし | 腎細胞がん | 2022年5月 | Tateyama M, Takeshima T, Iwasaki K. Reproduction of Control Groups in Two Global RCTs of Anti-cancer Drugs Using Health Insurance Claims Data in Japan. ISPOR 2022, May 15-18, 2022. Washington, DC, USA |
| ポスター | ボストン・サイエンティフィック | 重症下肢虚血 | 2022年5月 | Takashima K, Takeshima T, Tateyama M, Iwasaki K, Risk Factors for Amputation in Japanese Patients with Critical Limb Ischemia Based on a Claims Database Analysis. ISPOR 2022, May 15-18, 2022. Washington, DC, USA |
| その他 | 塩野義製薬 | 特発性肺線維症 | 2022年4月 | 近藤 康博、須田 隆文、本郷 良泳、吉田 真奈美、廣居 伸蔵、岩崎 宏介、武島 智美、本間 栄: 日本における特発性肺線維症に対する早期の抗線維化薬治療の 有効性の検討：データベース研究 presented in The 62nd Annual Meeting of The Japanese Respiratory Society in Kyoto Japan (April 22-24, 2022). |
| 論文 | なし | なし | 2022年3月 | 立山緑, 武島智美, 岩崎宏介. 新薬開発におけるヒストリカルコントロールデータの導入 ～アクチュアリーの貢献が必要な新領域～. JARIP Bulletin Vol. 5, 2021 No.2, 2022年3月 |
| 論文 | 塩野義製薬 | インフルエンザ | 2022年3月 | Shimizu E, Iwasaki K, Hongo Y, Yoshida M, Kinoshita M, Hiroi S, Tamura D. Diagnosis and treatment of influenza based on health insurance claims between the 2010-2011 and 2019-2020 influenza seasons in Japan. Influenza Other Respir Viruses. 2022 Mar 17. doi: 10.1111/irv.12977. Epub ahead of print. PMID: 35297196. |
| 論文 | 住友ファーマ | ２型糖尿病 | 2022年3月 | Nishimura R, Takeshima T, Iwasaki K, Aoi S. Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis. BMJ Open. 2022 Mar 11;12(3):e045966. doi: 10.1136/bmjopen-2020-045966. PMID: 35277396. |
| 論文 | ノバルティス | 多発性硬化症 | 2022年3月 | Kawachi I, Otaka H, Iwasaki K, Takeshima T, Ueda K. A Principal Component Analysis Approach to Estimate the Disability Status for Patients with Multiple Sclerosis Using Japanese Claims Data. Neurol Ther. 2022 Mar;11(1):385-396. doi: 10.1007/s40120-022-00324-0. Epub 2022 Jan 22. PMID: 35064908; PMCID: PMC8857383. |
| 論文 | 塩野義製薬 | 特発性肺線維症 | 2022年2月 | Kondoh Y, Suda T, Hongo Y, Yoshida M, Hiroi S, Iwasaki K, Takeshima T, Homma S. Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respir Res. 2022 Feb 8;23(1):24. doi: 10.1186/s12931-022-01938-6. PMID: 35135550; PMCID: PMC8822670. |
| 論文 | 塩野義製薬 | インフルエンザ | 2022年2月 | Kurazono K, Ikeoka H, Hiroi S, Iwasaki K, Takeshima T, Tamura D. Comparison of Inconvenience Costs Between Influenza Antivirals for Japanese Pediatric Patients: A Conjoint Analysis of Parental Responses. Adv Ther. 2022 Feb 21. doi: 10.1007/s12325-022-02062-z. Epub ahead of print. PMID: 35190996. |
| 論文 | 塩野義製薬 | 慢性肝炎 | 2021年12月 | Yoshida M, Tateishi R, Hiroi S, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A. Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data. Adv Ther. 2022 Feb;39(2):992-1003. doi: 10.1007/s12325-021-02008-x. Epub 2021 Dec 20. PMID: 34928469; PMCID: PMC8866341. |
| 論文 | 塩野義製薬 | インフルエンザ | 2021年12月 | Kurazono K, Ikeoka H, Hiroi S, Iwasaki K, Takeshima T, Akazawa M. Estimation of the cost of influenza antiviral medication guidance or support provided by healthcare professionals: a questionnaire survey in Japan. J Med Econ. 2022 Jan-Dec;25(1):38-50. doi: 10.1080/13696998.2021.2012073. PMID: 34842029. |
| 論文 | 住友ファーマ | ２型糖尿病 | 2021年11月 | Nishimura R, Taniguchi M, Takeshima T, Iwasaki K. Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis. Adv Ther. 2022 Jan;39(1):632-654. doi: 10.1007/s12325-021-01979-1. Epub 2021 Nov 30. PMID: 34846709; PMCID: PMC8799586. |
| 論文 | 塩野義製薬 | 慢性肝炎 | 2021年11月 | Yoshida M, Tateishi R, Hiroi S, Hongo Y, Fujiwara M, Kitanishi Y, Iwasaki K, Takeshima T, Igarashi A. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease. Adv Ther. 2022 Jan;39(1):379-390. doi: 10.1007/s12325-021-01965-7. Epub 2021 Nov 8. PMID: 34748184; PMCID: PMC8799534. |
| ポスター | なし | 肺がん | 2021年10月 | Tateyama M, Takeshima T, Iwasaki K, Comparison between comparison group of CASPIAN trial and its reproduction by Medicare 5% sample data, ACEP 21, 13-15 October 2021 |
| 論文 | 武田薬品工業 | 不眠症 | 2021年6月 | Makoto Uchiyama, Kazuo Mishima, Yoshitaka Kaneita,Kentaro Yamato, Manami Yoshida, Shinzo Hiroi, Kosuke Iwasaki, Shuichi Okamoto, Katsuhito Murase. Pharmacotherapy Status for Insomnia and Associated Femoral Fracture Risk Based on Real-World Data Analysis of DPC Hospitals in Japan: Hypnotic Class Comparison.睡眠医療 第15巻第2号. 2021/6/30 |
| 論文 | 住友ファーマ | ２型糖尿病 | 2021年6月 | Odawara M, Aoi S, Takeshima T, Iwasaki K. Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study. Diabetes Ther. 2021 Aug;12(8):2165-2177. doi: 10.1007/s13300-021-01101-2. Epub 2021 Jul 4. PMID: 34218420; PMCID: PMC8342731. |
| ポスター | DeSCヘルスケア | ２型糖尿病 | 2021年5月 | Iwasaki K. Nakano K. Mori M. Igarashi A. Changes in Cost of Oral Antidiabetic Drugs by Introduction of Formularies in Japan, A Simulation Using Health Insurance Claims Database. Virtual ISPOR 2021. May 17-20. |
| 論文 | なし | なし | 2021年5月 | Akifumi Hagiwara, Yujiro Otsuka, Christina Andica, Shimpei Kato, Kazumasa Yokoyama, Masaaki Hori, Shohei Fujita, Koji Kamagata, Nobutaka Hattori, Shigeki Aoki. Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorders by multiparametric quantitative MRI using convolutional neural network. Journal of Clinical Neuroscience. Volume 87, May 2021, Pages 55-58. |
| 論文 | 住友ファーマ | ２型糖尿病 | 2021年3月 | Nagai Y, Kazumori K, Takeshima T, Iwasaki K, Tanaka Y. A Claims Database Analysis of Dose-Dependency of Metformin and Incidence of Lactic Acidosis in Japanese Patients with Type 2 Diabetes. Diabetes Ther. 2021 Apr;12(4):1129-1141. doi: 10.1007/s13300-021-01029-7. Epub 2021 Mar 7. PMID: 33677755; PMCID: PMC7994465. |
| 論文 | 住友ファーマ | ２型糖尿病 | 2021年2月 | Yoshio Nagai, Kiyoyasu Kazumori, Tomomi Takeshima, Kosuke Iwasaki, Yasushi Tanaka. Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes. Diabetes Therapy(2021). 17 February 2021 |
| 論文 | 塩野義製薬 | インフルエンザ | 2021年1月 | Hosogaya N, Takazono T, Yokomasu A, Hiroi S, Ikeoka H, Iwasaki K, Takeshima T, Mukae H. Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis. J Med Econ. 2021 Jan-Dec;24(1):244-254. doi: 10.1080/13696998.2021.1877150. PMID: 33470138. |
| ポスター | 塩野義製薬 | 慢性肝炎 | 2020年11月 | Kosuke Iwasaki, Tomomi Takeshima, Yoshikazu Yusa. Prediction of Individual Differences in Progression of LIVER Fibrosis Based on Change in FIB-4 INDEX. Virtual ISPOR Europe 2020,16-19 November 2020 |
| ポスター | なし | ２型糖尿病 | 2020年11月 | Shotaro Maedera, Tomomi Takeshima, Ayano Chida, Yoshikazu Yusa, Kosuke Iwasaki, Nobuhiro Shojima, Tomohide Yamada. Development of Optimal Dynamic Treatment Regime to Enhance Adherence of Patients with Type 2 Diabetes with Q-Learning Using Claims DATA. A Virtual ISPOR Europe 2020,16-19 November 2020 |
| ポスター | なし | なし | 2020年11月 | Tomomi Takeshima, Kosuke Iwasaki, Ayako Kanegasaki, Yoshikazu Yusa ,Yasuhiro Makino. Association between Surgery and Development of Depression Based on a Claims Database Analysis.Virtual ISPOR Europe 2020,16-19 November 2020 |
| その他 | 住友ファーマ | ２型糖尿病 | 2020年10月 | 西村理明, 青井澄子, 馬塲健次, 武島智美, 岩崎宏介. 日本人2型糖尿病患者におけるメトホルミンとDPP-4阻害薬の心血管系合併症抑制作用の比較検討：医療情報データベース解析. 第63回日本糖尿病学会. 2020年10月5日～16日 |
| その他 | 塩野義製薬 | 特発性肺線維症 | 2020年9月 | Yasuhiro Kondoh, Takafumi Suda, Yoshie Hongo, Manami Yoshida, Shinzo Hiroi, Kosuke Iwasaki, Tomomi Takeshima, Sakae Homma.Prevalence of idiopathic pulmonary fibrosis in Japan and the US: a claims based retrospective study. ERS INTERNATIONAL CONGRESS 2020 Virtual, 7-9 September, 2020 |
| その他 | ノバルティス | 多発性硬化症 | 2020年9月 | H.Otaka, K.Ueda, K.Iwasaki, T.Takeshima, I.Kawachi. Prediction of MS disability status in Japanese claims database using principal component analysis. the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020, 2020 Sep.11-13 |
| ポスター | なし | ２型糖尿病 | 2020年8月 | Maedera S, Takeshima T, Chida A, Iwasaki K, Shojima N, Yamada T. A DYNAMIC TREATMENT REGIME MODEL TO ENHANCE ADHERENCE OF PATIENTS WITH TYPE 2 DIABETES WITH Q-LEARNING.ISCB41 Kraków 2020 Virtual Conference, 23-27 August 2020 |
| 論文 | アステラス製薬 | 便秘症 | 2020年8月 | Hiroyuki Okumura, Wentao Tang, Kosuke Iwasaki, Shingo Shoji, Takeo Odaka, Atsushi Nakajima.Comparative Efficacy of Linaclotide Versus Other Oral Constipation Treatments in Chronic Constipation: a Network Meta-analysis.SN Comprehensive Clinical Medicine 18 August 2020 .doi.org/10.1007/s42399-020-00467-x |
| 論文 | 武田薬品工業 | パーキンソン病 | 2020年7月 | Suzuki M, Arai M, Hayashi A, Ogino M. Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database. eNeurologicalSci. 2020 Jul 16;20:100257. doi: 10.1016/j.ensci.2020.100257. PMID: 32775705; PMCID: PMC7397691. |
| 論文 | 武田薬品工業 | パーキンソン病 | 2020年4月 | Suzuki M, Arai M, Hayashi A, Ogino M. Adherence to treatment guideline recommendations for Parkinson's disease in Japan: A longitudinal analysis of a nationwide medical claims database between 2008 and 2016. PLoS One. 2020 Apr 24;15(4):e0230213. doi: 10.1371/journal.pone.0230213. PMID: 32330133; PMCID: PMC7182259. |
| 論文 | なし | なし | 2020年4月 | Shohei Fujita, Akifumi Hagiwara, Yujiro Otsuka, Masaaki Hori, Naoyuki Takei, Ken-Pin Hwang , Ryusuke Irie, Christina Andica, Koji Kamagata, Toshiaki Akashi, Kanako Kunishima Kumamaru, Michimasa Suzuki, Akihiko Wada, Osamu Abe, Shigeki Aoki. Deep Learning Approach for Generating MRA Images From 3D Quantitative Synthetic MRI Without Additional Scans. INVESTIGATIVE RADIOLOGY, 2020 Apr;55(4):249-256. doi: 10.1097/RLI.0000000000000628. |
| 論文 | ベーリンガーインゲルハイム | ２型糖尿病 | 2020年4月 | Yasuhisa Ono, Yusuke Taneda, Tomomi Takeshima, Kosuke Iwasaki, Atsutaka Yasui. Validity of Claims Diagnosis Codes for Cardiovascular Diseases in Diabetes Patients in Japanese Administrative Database. Clinical Epidemiology. 2020 Apr 8;12:367-375. doi: 10.2147/CLEP.S245555. |
| 論文 | なし | ２型糖尿病 | 2020年3月 | Tomohide Yamada, Kosuke Iwasaki, Shotaro Maedera, Katsuya Ito, Tomomi Takeshima, Hisashi Noma & Nobuhiro Shojima. Myocardial infarction in type 2 diabetes using sodium–glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning. Current Medical Research and Opinion. Volume 36, 2020 - Issue 3. 2020 March |
| 論文 | 武田薬品工業 | 多発性硬化症 | 2019年12月 | Kawachi I, Okamoto S, Sakamoto M, Ohta H, Nakamura Y, Iwasaki K, Yoshida M, Hiroi S, Ogino M. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database. BMC Neurol. 2019 Dec 16;19(1):324. doi: 10.1186/s12883-019-1534-9. PMID: 31842786; PMCID: PMC6912943. |
| 論文 | セルジーン | 多発性骨髄腫 | 2019年11月 | Uno S, Goto R, Suzuki K, Iwasaki K, Takeshima T, Ohtsu T. Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database. J Med Econ. 2020 Feb;23(2):166-173. doi: 10.1080/13696998.2019.1686870. Epub 2019 Nov 18. PMID: 31682533. |
| ポスター | なし | パーキンソン病 | 2019年11月 | Ataru Igarashi, Tomomi Takeshima, Kosuke Iwasaki. ASSOCIATION BETWEEN TYPE OF SURGERY AND DEVELOPMENT OF PARKINSON’S DISEASE: A NESTED CASE-CONTROL STUDY USING A US INSURANCE CLAIMS DATA. ISPOR Europe 2019, 2-6 November 2019, Copenhagen, Denmark |
| ポスター | 塩野義製薬 | 特発性肺線維症 | 2019年11月 | Yoshie Hongo, Yasuhiro Kondoh, Takafumi Suda, Manami Yoshida, Shinzo Hiroi, Kosuke Iwasaki, Tomomi Takeshima, Sakae Homma. CURRENT TREATMENT STATUS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IN JAPAN: A CLAIMS-BASED RETROSPECTIVE STUDY. ISPOR Europe 2019, 2-6 November 2019, Copenhagen, Denmark |
| ポスター | 塩野義製薬 | 慢性肝炎 | 2019年11月 | Manami Yoshida, Ryosuke Tateishi, Shinzo Hiroi, Yoshie Hongo, Masakazu Fujiwara, Yoshitake Kitanishi, Kosuke Iwasaki, Tomomi Takeshima, Ataru Igarashi. THE RECENT CHANGE IN EPIDEMIOLOGY OF CHRONIC LIVER DISEASE IN JAPAN: AN ANALYSIS OF CLAIMS DATABASE. ISPOR Europe 2019, 2-6 November 2019, Copenhagen, Denmark |
| その他 | ノバルティス | 心不全 | 2019年10月 | 江口駿介、三谷博信、森田洋平、金ヶ崎彩子、岩崎宏介、吉川勉、大山尚貢。日本人心不全患者における繰り返し入院の現状：DPCデータを用いた後ろ向き解析。第23回日本心不全学会学術集会、2019年10月4日（金）〜6日（日）、広島国際会議場 |
| その他 | 塩野義製薬 | 慢性肝炎 | 2019年10月 | Manami Yoshida, Ryosuke Tateishi, Shinzo Hiroi, Masakazu Fujiwara, Yoshitake Kitanishi, Kosuke Iwasaki, Tomomi Takeshima, Ataru Igarashi. The Associated Risk of Thrombocytopenia in Patients with Chronic Liver: Disease based on an Analysis Using Real-World-Data in Japan. JSH International Liver Conference 2019, 2019 October 1 - 2, Osaka |
| 論文 | なし | なし | 2019年8月 | Alice Le Berre, Koji Kamagata, Yujiro Otsuka, Christina Andica, Taku Hatano, Laetitia Saccenti, Takashi Ogawa, Haruka Takeshige-Amano, Akihiko Wada, Michimasa Suzuki, Akifumi Hagiwara, Ryusuke Irie, Masaaki Hori, Genko Oyama, Yashushi Shimo, Atsushi Umemura, Nobutaka Hattori & Shigeki Aoki . Convolutional neural network-based segmentation can helpin assessing the substantia nigra in neuromelanin MRI. Neuroradiology volume 61, pages1387–1395(2019), 2019 August 10. DOI: 10.1007/s00234-019-02279-w |
| 論文 | 住友ファーマ | パーキンソン病 | 2019年7月 | Hirotaka Iwaki, Masaaki Tagawa, Kosuke Iwasaki, Koji Kawakami, Masahiro Nomoto “Comparison of zonisamide with non-levodopa, anti-Parkinson’s disease drugs in the incidence of Parkinson’s disease-relevant symptoms” Journal of the Neurological Sciences. 2019 Jul 15;402:145-152. doi: 10.1016/j.jns.2019.05.028. Epub 2019 May 24. |
| 論文 | 武田薬品工業 | ピロリ菌 | 2019年6月 | Deguchi H, Uda A, Murakami K. Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database. Digestion. 2020;101(4):441-449. doi: 10.1159/000500819. Epub 2019 Jun 19. PMID: 31216549; PMCID: PMC7384341. |
| 論文 | なし | なし | 2019年6月 | Kanako K. Kumamaru, Shinichiro Fujimoto, Yujiro Otsuka, Tomohiro Kawasaki, Yuko Kawaguchi, Etsuro Kato, Kazuhisa Takamura, Chihiro Aoshima, Yuki Kamo, Yosuke Kogure, Hidekazu Inage, Hiroyuki Daida, Shigeki Aoki “Diagnostic accuracy of 3D deep-learning-based fully automated estimation of patient-level minimumfractional flow reserve from coronary computed tomography angiography” European Heart Journal – Cardiovascular Imaging. 2019 Jun 23. pii: jez160. doi: 10.1093/ehjci/jez160. |
| ポスター | なし | インフルエンザ | 2019年5月 | Kanegasaki A, Iwasaki K “Assessment of the influence of influenza vaccines and antiviral drugs administration on medical expenses after influenza infection” ISPOR 2019. May 18-22, 2019, New Orleans, LA, USA |
| ポスター | なし | 脂質異常症 | 2019年5月 | Ataru Igarashi, Tomomi Takeshima, Kosuke Iwasaki “CURRENT TREATMENT STATUS WITH PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 INHIBITORS IN PATIENTS BASED ON A REAL-WORLD DATA ANALYSIS IN USA” ISPOR 2019. 2019 May 18-22, New Orleans, LA, USA |
| 論文 | 武田薬品工業 | 高血圧 | 2019年5月 | Mitsuru Ohishi, Takuo Yoshida, Nobuhiro Nishigaki, Akinori Oh & Yukio Shimasaki “Antihypertensive treatment for hypertensive patients with heart failure using real-world Japanese data: subanalysis of the Retrospective study of antihypertensives for lowering blood pressure (REAL) study” Clinical and Experimental Hypertension. 2019 Mar 26:1-7. doi: 10.1080/10641963.2019.1590384. |
| 論文 | なし | ２型糖尿病 | 2019年4月 | 唐文涛，岩崎宏介 “基于日本医 疗 大数据的糖尿病诊疗延误负担的经济学评价” CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE.Apr 2019, Vol. 19, No.4 |
| 論文 | 武田薬品工業 | 高血圧 | 2019年3月 | Mitsuru Ohishi, Takuo Yoshida, Akinori Oh, Shinzo Hiroi, Tomomi Takeshima, Yujiro Otsuka, Kosuke Iwasaki, Yukio Shimasaki. Analysis of antihypertensive treatment using real-world Japanesedata—the retrospective study of antihypertensives for loweringblood pressure (REAL) study.Hypertens Research. 2019 Jul;42(7):1057-1067. doi: 10.1038/s41440-019-0238-2. Epub 2019 Mar 6. |
| 論文 | 武田薬品工業 | 逆流性食道炎 | 2019年3月 | Miyazaki H, Igarashi A, Takeuchi T, Teng L, Uda A, Deguchi H, Higuchi K, Tango T “Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review” J Gastroenterol Hepatol. 2019 Mar 18. doi: 10.1111/jgh.14664. |
| 論文 | 武田薬品工業 | 逆流性食道炎 | 2019年3月 | Miwa H, Igarashi A, Teng L, Uda A, Deguchi H, Tango T. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. J Gastroenterol. 2019 Aug;54(8):718-729. doi: 10.1007/s00535-019-01572-y. Epub 2019 Mar 27. PMID: 30919071; PMCID: PMC6647489. |
| 論文 | 武田薬品工業 | 高血圧 | 2019年3月 | Ohishi M, Yoshida T, Oh A, Hiroi S, Takeshima T, Otsuka Y, Iwasaki K, Shimasaki Y. Analysis of antihypertensive treatment using real-world Japanese data-the retrospective study of antihypertensives for lowering blood pressure (REAL) study. Hypertens Res. 2019 Jul;42(7):1057-1067. doi: 10.1038/s41440-019-0238-2. Epub 2019 Mar 6. PMID: 30842611; PMCID: PMC8075880. |
| その他 | アムジェン | 骨折 | 2019年2月 | 岩崎宏介. 日本における骨折による介護負担とその推移 ―官庁統計を用いた分析. Milliman Report |
| その他 | セルジーン | 多発性骨髄腫 | 2018年12月 | Shuji Uno, Kazushige Saito, Danilo Janune, Kosuke Iwasaki, Tomoko Ohtsu. The Current Situation of Multiple Myeloma Treatment in Japan: A Cross-Sectional Analysis Based on Health Insurance Claims Data. 60th ASH Annual Meeting and Exposition; December 1-4, 2018; San Diego, CA |
| ポスター | なし | ２型糖尿病 | 2018年11月 | Kanegasaki A, Iwasaki K. Assessment of oral antidiabetic drug-medicated glycemic control in patients with type 2 diabetes mellitus. ISPOR Europe 2018. 10-14 November 2018. Barcelona, Spain |
| ポスター | なし | ２型糖尿病 | 2018年11月 | Yamada T, Ito K, Takeshima T, Iwasaki K, Shojima N, Yamauchi T, Kadowaki T. Association Between Class if Antidiabetic Drug And Incidence of Myocardial Infarction In Patients with Type 2 Diabetes Melitus: A Proportional Hazard Analysis Using Deep Learning For Risk Adjustment. ISPOR Europe 2018. 10-14 November 2018. Barcelona, Spain |
| ポスター | 日本システム技術 | 白内障 | 2018年11月 | Aoki R, Matsui T, Tang W, Iwasaki K, Tamura M. A cost-effectiveness analysis of cataract surgery in Japan using claims data. ISPOR Europe 2018. 10-14 November 2018. Barcelona, Spain |
| ポスター | メディリード | なし | 2018年11月 | Kanegasaki,Shoji,Iwasaki, Kokubo. DEVELOPMENT OF MACHINE LEARNING-BASED ABSTRACT DOCUMENT CLASSIFICATION FOR SUPPORTING SYSTEMATIC REVIEWS. ISPOR Europe 2018. 10-14 November 2018. Barcelona, Spain |
| ポスター | アステラス製薬 | 便秘症 | 2018年11月 | H Okumura,W Tang, K Iwasaki, S Shoji,1 Odaka, A Nakajima, Systematic literature review and indirect treatment comparison of linaclotide versus other oral constipation treatments in patients with chronic constipation, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe; 10-14 November 2018; Barcelona, Spain |
| その他 | なし | ２型糖尿病 | 2018年10月 | 山田朋英、武島智美、伊藤克哉、 岩崎宏介、庄嶋伸浩、山内敏正、門脇孝. 米国健康保険給付データにおける 2型糖尿病患者の心筋梗塞発生率 機械学習によるリスク調整後の薬剤間比較. 2018年10月13日. 日本薬剤疫学会 |
| 論文 | なし | なし | 2018年9月 | Yukihiro Koretsune, Takeshi Yamashita, Masahiro Yasaka, Yasuhisa Ono, Takeshi Hirakawa, Kosuke Ishida, Daisuke Kuroki, Toshiyuki Sumida, Hisashi Urushihara.Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis. Journal of Cardiology. Accepted 18 September 2018 |
| 論文 | 武田薬品工業 | ピロリ菌 | 2018年9月 | Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019 May;22(3):435-445. doi: 10.1007/s10120-018-0876-0. Epub 2018 Sep 11. PMID: 30206731. |
| ポスター | なし | ２型糖尿病 | 2018年9月 | Iwasaki K, Nakamura M, Takeshima T. DEVELOPMENT OF A PREDICTIVE MODEL OF HEMOGLOBIN A1C BASED ON STATISTICAL MACHINE LEARNING USING CLINICAL DATA. ISPOR Asia Pacific 2018. 8-11 September 2018. Tokyo, Japan |
| ポスター | 日本システム技術 | なし | 2018年9月 | Takeshima T, Keino S, Aoki R, Matsui T, Iwasaki K. DEVELOPMENT OF A MEDICAL COST PREDICTION MODEL BASED ON STATISTICAL MACHINE LEARNING USING HEALTH INSURANCE CLAIMS DATA. ISPOR Asia Pacific 2018. 8-11 September 2018. Tokyo, Japan |
| 論文 | オムロンヘルスケア | 月経前症候群 | 2018年9月 | Song M, Kanaoka H. Effectiveness of mobile application for menstrual management of working women in Japan: randomized controlled trial and medical economic evaluation. J Med Econ. 2018 Nov;21(11):1131-1138. doi: 10.1080/13696998.2018.1515082. Epub 2018 Sep 10. PMID: 30130990. |
| 論文 | ベーリンガーインゲルハイム | ２型糖尿病 | 2018年8月 | Kadowaki T, Sarai N, Hirakawa T, Taki K, Iwasaki K, Urushihara H. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis. Diabetes Obes Metab. 2018 Dec;20(12):2830-2839. doi: 10.1111/dom.13463. Epub 2018 Aug 2. PMID: 29974673; PMCID: PMC6282986. |
| その他 | 武田薬品工業 | 不眠症 | 2018年7月 | 稲田健, 榎本みのり, 山戸健太郎, 吉田真奈美, 岩崎宏介, 岡本秀一, 三島和夫. 診療データを用いた睡眠薬の処方実態と継続期間に関する分析. 日本睡眠学会学術集会. ２０１８年７月１１日～１３日 札幌コンベンションセンター |
| その他 | なし | 心筋梗塞 | 2018年7月 | Noriyuki Kogo, Kosuke Iwasaki, Daiki Kanazawa, Yoshiyuki Kuno. Predicting Incidences Of Acute Myocardial Infarctions: Are Big Data And Machine Learning Algorithms Useful For Predictive Models?. International Congress of Actuaries, June 2018 |
| 論文 | ヤンセン | 乾癬 | 2018年7月 | Sruamsiri R, Iwasaki K, Tang W, Mahlich J. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018 Jul 11;18(1):5. doi: 10.1186/s12895-018-0074-0. PMID: 29996929; PMCID: PMC6042444. |
| ポスター | JMDC | ２型糖尿病 | 2018年6月 | Kosuke Iwasaki, Tomomi Takeshima, Daiki Kanazawa, Yoshiyuki Kuno. Relationship Between Hemoglobin A1c And Medical Costs In Japan. HTAi 2018. June 04, 2018 |
| ポスター | JMDC | なし | 2018年6月 | Tomomi Takeshima, Kosuke Iwasaki, Daiki Kanazawa, Yoshiyuki Kuno. Relationship Of Self-Reported Sleep Quality To Disease Status In Japan. HTAi 2018. June 04, 2018 |
| ポスター | なし | がん | 2018年6月 | Kosuke Iwasaki, Wentao Tang, Tomomi Takeshima. INCIDENCE OF MALIGNANT NEOPLASM FOR PATIENTS USING BIOLOGIC DRUGS: A NESTED CASE-CONTROL STUDY USING MEDICARE 5% SAMPLE DATASETS. ISPOR. June 2018 |
| その他 | 武田薬品工業 | パーキンソン病 | 2018年5月 | 鈴木正彦、吉田真奈美、新居賢樹、林亜矢子、安羅有紀、廣居伸蔵、岡本秀一、荻野美恵子.MDV診療データベースを用いた抗パーキンソン病薬の処方実態に関する検討. 第59回日本神経学会学術大会. 2018年5月 |
| 論文 | ファイザー | 喫煙 | 2018年5月 | Suwa K, Yoshikawa R, Iwasaki K, Igarashi A. The association between smoking cessation outpatient visits and total medical costs: a retrospective, observational analysis of Japanese employee-based public health insurance data. J Med Econ. 2018 May;21(5):443-449. doi: 10.1080/13696998.2018.1426590. Epub 2018 Feb 1. PMID: 29316823. |
| 論文 | 武田薬品工業 | 多発性硬化症 | 2018年4月 | Ogino M, Shiozawa A, Ota H, Okamoto S, Hiroi S, Kawachi I. Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data. Neurodegener Dis Manag. 2018 Apr;8(2):97-103. doi: 10.2217/nmt-2017-0047. Epub 2018 Apr 25. PMID: 29694267. |
| その他 | 武田薬品工業 | 潰瘍性大腸炎 | 2018年4月 | 小林拓. 診療データベースを用いた 本邦における潰瘍性大腸炎に対する 抗TNFα抗体製剤の使用実態解析, 2018.4.20 日本消化器病学会 (東京) |
| その他 | 武田薬品工業 | 潰瘍性大腸炎 | 2018年4月 | 小林拓. 診療データベースを用いた 本邦における潰瘍性大腸炎に対する ステロイドの使用実態解析, 2018.4.20 日本消化器病学会 (東京) |
| 論文 | 武田薬品工業 | 潰瘍性大腸炎 | 2018年2月 | T Kobayashi, A Uda, T Mineyama, E Udagawa, K Iwasaki, W Tang, T Hibi, P506 Incidence risk of colorectal cancer, non-melanoma skin cancers and non-Hodgkin lymphoma in Japanese patients with ulcerative colitis based on large-scale claims database, Journal of Crohn's and Colitis, Volume 12, Issue supplement_1, February 2018, Pages S360–S361, https://doi.org/10.1093/ecco-jcc/jjx180.633 |
| その他 | 武田薬品工業 | がん | 2018年2月 | 三代泉, 廣居伸蔵. 日本におけるがん罹患の離職に対する影響：大規模保険給付データベースを用いたリアル・ワールド・エビデンス.第28回日本疫学会学術総会.2018年2月1日～3日 |
| 論文 | 大塚製薬 | パーキンソン病 | 2017年12月 | Nomoto M, Iwaki H, Kondo H, Sakurai M. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials. J Neurol. 2018 Feb;265(2):253-265. doi: 10.1007/s00415-017-8671-0. Epub 2017 Nov 21. Erratum in: J Neurol. 2017 Dec 21;: PMID: 29164312; PMCID: PMC5808069. |
| その他 | 武田薬品工業 | 潰瘍性大腸炎 | 2017年12月 | 小林拓、宇田晃仁、廣居伸蔵、中村和紀、峯山智佳、唐文涛、岩崎宏介、日比紀文。診療データベースを用いた本邦における 潰瘍性大腸炎薬物治療実態の解析。第８回日本炎症性腸疾患学会学術集会。2017年12月1日-2日 |
| その他 | 武田薬品工業 | 不眠症 | 11/1/2017 | 山戸健太郎、吉田真奈美、廣居伸蔵、岡本秀一。睡眠薬の処方実態に関する リアルワールドデータ分析。第27回日本臨床精神神経薬理学会。2017年11月2日-3日 |
| その他 | 武田薬品工業 | 不眠症 | 2017年11月 | 山戸健太郎、吉田真奈美、廣居伸蔵、岡本秀一。レセプトデータベースを用いたベンゾジアゼピン系睡眠薬の処方実態に関する検討。第27回日本臨床精神神経薬理学会。2017年11月2日-3日 |
| その他 | 武田薬品工業 | 高血圧 | 2017年10月 | 大石充、吉田拓生、岩崎宏介、黄章徳、西垣信裕、廣居伸蔵、嶋﨑幸生。心不全合併高血圧患者における利尿薬の使用実態調査REAL study :REtrospective study of Antihypertensives for Lowering blood pressure -。第40回 日本高血圧学会総会。2017.10.21 |
| その他 | ベーリンガーインゲルハイム | ２型糖尿病 | 2017年10月 | 門脇 孝，皿井 伸明，平河 威，瀧 健太郎，岩崎 宏介，漆原 尚巳。大規模病院情報データベースを用い腎機能別に解析した2型糖尿病患者の臨床的特徴と経口血糖降下薬による治療継続性の検討。第32回日本糖尿病合併症学会。2017年10月27-29日 |
| その他 | 武田薬品工業 | 逆流性食道炎 | 2017年10月 | Igarashi A. 逆流性食道炎患者における ネットワークメタアナリシス研究. JDDW 2017 Breakfast Seminar 12 OCT 2017 |
| 論文 | 武田薬品工業 | なし | 2017年9月 | Hiroi S, Kubota K, Mishiro I, Fernandez JL. Post-marketing surveillance in Japan: Potential best way forward. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1138-1139. doi: 10.1002/pds.4290. PMID: 28913964. |
| その他 | 武田薬品工業 | ピロリ菌 | 2017年9月 | Murakami K, Deguchi H, Uda A, Hiroi S, Ueda K. Current status of Japanese H.pylori eradication therapy based on a nationwide clinical database analysis. European Helicobacter & Microbiota Study Group, Bordeaux, France, Sep 7-9, 2017. |
| 論文 | 武田薬品工業 | 多発性硬化症 | 2017年9月 | Ogino M, Okamoto S, Ohta H, Sakamoto M, Nakamura Y, Iwasaki K, Yoshida M, Hiroi S, Kawachi I. Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database. Clin Exp Neuroimmunol. 2017 Nov;8(4):318-326. doi: 10.1111/cen3.12411. Epub 2017 Sep 4. PMID: 29242717; PMCID: PMC5724648. |
| その他 | 武田薬品工業 | 逆流性食道炎 | 2017年9月 | 五十嵐 中、丹後 俊郎、滕 麗達、大塚 裕次朗、岩崎 宏介、三輪 洋人。逆流性食道炎の維持効果におけるボノプラザンと既存のPPIの比較：ネットワークメタアナリシスによる検討。日本臨床疫学会 第1回年次学術大会、東京、2017年9月30－10月1日。 |
| その他 | 武田薬品工業 | ピロリ菌 | 2017年9月 | 廣居 伸蔵、菅野 健太郎、田中 司朗、川上 浩司。ピロリ菌除菌に対する保険適用の効果：リアルワールドデータに基づく観察研究と将来予測。日本臨床疫学会 第1回年次学術大会、東京、2017年9月30－10月1日。 |
| その他 | 武田薬品工業 | 乳がん | 2017年9月 | 後藤 励、宇田 晃仁、廣居 伸蔵、岩崎 宏介、大家 基嗣、紅林 淳一。リュープロレリン酢酸塩注射用製剤6か月持続製剤と3か月持続製剤の費用分析による医療経済効果の比較。日本臨床疫学会 第1回年次学術大会、東京、2017年9月30－10月1日。 |
| 論文 | 武田薬品工業 | 乳がん | 2017年8月 | Goto R, Uda A, Hiroi S, Iwasaki K, Takashima K, Kurebayashi J. Cost analysis of leuprorelin acetate in Japanese premenopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations. J Med Econ. 2017 Aug 16:1-7. |
| 論文 | 武田薬品工業 | 前立腺がん | 2017年8月 | Goto R, Uda A, Hiroi S, Iwasaki K, Takashima K, Oya M. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: Comparison between 6-month and 3-month depot formulations. J Med Econ. 2017 Aug 16:1-8. |
| その他 | 武田薬品工業 | パーキンソン病 | 2017年8月 | Yoshida M, Uda A, Hiroi S, Okamoto S. The current treatment of Parkinson's disease in Japan: a retrospective Japanese claims database analysis. The 21st International Epidemiological Association and World Congress of Epidemiology, Saitama, Japan, August 19-22, 2017. |
| その他 | 武田薬品工業 | がん | 2017年8月 | Mishiro I, Hiroi S. Impact of cancer on subsequent disemployment risk among Japanese work-age men and women: real world evidence from a large-scale claims database in Japan. The 21st International Epidemiological Association and World Congress of Epidemiology, Saitama, Japan, August 19-22, 2017. |
| 論文 | 武田薬品工業 | ピロリ菌 | 2017年7月 | Hiroi S, Sugano K, Tanaka S, Kawakami K. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open. 2017 Jul 31;7(7):e015855. doi: 10.1136/bmjopen-2017-015855. PMID: 28760790; PMCID: PMC5642792. |
| ポスター | ウェルビー | なし | 2017年6月 | Takeshima T, Iwasaki K, Inoue H, Hiki T. Relation Between Pain And Treatment/Activity Based On Mobile App Data. HTAi 2017 Annual Meeting, Rome, Italy, June 17-21, 2017. |
| ポスター | JMDC | なし | 2017年6月 | Iwasaki K, Kuno Y, Kanazawa D, Takeshima T, Takashima K, Nakamura Y. Will a proposed policy in Japan, Health Gold License, work?: Estimation of medical cost saved by medical check-ups. HTAi 2017 Annual Meeting, Rome, Italy, June 17-21, 2017. |
| その他 | 武田薬品工業 | ピロリ菌 | 2017年6月 | 出口尚人、村上和成。大規模診療データベースに基づいた我が国におけるピロリ菌診断の実態と問題点。第23回日本ヘリコバクター学会、北海道函館市、2017年6月30日－7月2日。 |
| その他 | 武田薬品工業 | 不眠症 | 2017年6月 | 201706 内山真、三島和夫、兼板佳孝、山戸健太郎、吉田真奈美、廣居伸蔵、岩崎宏介、村瀬勝人、岡本秀一。不眠症治療薬の処方実態と転倒リスクに関するリアルワールドデータ分析。日本睡眠学会第42回定期学術集会、神奈川県横浜市、2017年6月29－30日。 |
| ポスター | 武田薬品工業 | 多発性骨髄腫 | 2017年6月 | Jun G, Mishiro I, Hiroi S, Skacel T, Iwasaki K, Soeda J. Treatment patterns and duration of treatment in Japanese multiple myeloma patients receiving second line therapy with novel agents. The 22nd Congress of the European Hematology Association, Madrid, Spain, June 22 - 25, 2017. |
| ポスター | 武田薬品工業 | 逆流性食道炎 | 2017年5月 | Miwa H, Tango T, Igarashi A, Teng L, Otsuka Y, Iwasaki K. A systematic review and network meta-analysis of comparative efficacy among vonoprazan and proton pump inhibitors for maintenance treatment of reflux esophagitis. Digestive Disease Week 2017, Chicago, May 6-9, 2017 |
| ポスター | 武田薬品工業 | 逆流性食道炎 | 2017年5月 | Higuchi K, Tango T, Igarashi A, Teng L, Otsuka Y, Iwasaki K. A systematic review and network meta-analysis of comparative efficacy among vonoprazan and proton pump inhibitors for healing of reflux esophagitis. Digestive Disease Week 2017, Chicago, May 6-9, 2017 |
| ポスター | 武田薬品工業 | ２型糖尿病 | 2017年5月 | Iwasaki K, Oh A, Hiroi S. Modeling individual patient blood glucose levels as a stochastic process: An observational study using laboratory data from hospitals in Japan. 22nd Annual of ISPOR, Boston, USA, 20-24 May, 2017. |
| その他 | 武田薬品工業 | 高血圧 | 2017年3月 | Ohishi M, Yoshida T, Iwasaki K, Hiroi S, Shimasaki Y. Prescription status of antihypertensive in Japan based on real-world data. 第81回日本循環器学会学術集会、石川県金沢市、2017年3月17-19日。 |
| ポスター | 武田薬品工業 | 多発性骨髄腫 | 2016年12月 | Jun G, Luptakova K, Koizumi H, Iwasaki K, Hiroi S, Soeda J. Patient characteristics, treatment patterns and outcomes among relapsed/refractory multiple myeloma (RRMM) patients in Japan. The 57th American Society of Hematology Annual Meeting, San Diego, USA, Dec 3-6, 2016. |
| その他 | 武田薬品工業 | ２型糖尿病 | 2016年11月 | 武島智美、岩崎宏介、廣居伸蔵、宇田晃仁、加藤晴香、嶋崎幸生。高齢者糖尿病の血糖コントロール目標に関するＲＷＤを用いた分析。第22回日本薬剤疫学会学術総会、京都市、2016年11月18－20日。 |
| ポスター | 武田薬品工業 | ２型糖尿病 | 2016年10月 | Takeshima T, Nakamura Y, Iwasaki K, Hiroi S, Uda A, Yoshida M, Kato H, Shimasaki Y. Comorbidity of depression and type 2 diabetes: a retrospective Japanese claims database analysis. ISPOR 19th Annual European Congress, Vienna, Austria, Oct 29 –Nov 2, 2016. |
| ポスター | 武田薬品工業 | 高血圧 | 2016年10月 | Koizumi H, Iwasaki K, Uda A, Hiroi S , Oh A, Shimasaki Y. Analysis of the relationship between blood pressure in health checkup and effectiveness of antihypertensive. ISPOR 19th Annual European Congress, Vienna, Austria, Oct 29 –Nov 2, 2016. |
| ポスター | 武田薬品工業 | なし | 2016年10月 | Hiroi S, Uda A, Mishiro I, Tokaji A, Takeshima T, Iwasaki K. Ethical standards in reporting research from retrospective observational studies based on databases using anonymous and personally unidentifiable data. ISPOR 19th Annual European Congress, Vienna, Austria, Oct 29 –Nov 2, 2016. |
| その他 | 関東労災病院 | なし | 2016年9月 | 小西竜太、松山科子、岩崎宏介。Bayesian Network Modelの病院リスクマネジメントへの適応。日本医療病院管理学会。2016年9月17日 |
| ポスター | なし | なし | 2016年9月 | Nakamura Y, Hirata S, Iwasaki K. Bayesian Network of Disease History. ISPOR 7th Asia-Pacific Conference, Singapore, Sep 3-6, 2016. |
| ポスター | 武田薬品工業 | 多発性硬化症 | 2016年9月 | Ogino M, Shiozawa A, Ohta H, Okamoto S, Hiroi S, Otake K, Takeshima T, Iwasaki K, Kawachi I. Prevalence and patient characteristics of multiple sclerosis (MS) in Japan. ISPOR 7th Asia-Pacific Conference, Singapore, Sep 3-6, 2016. |
| 論文 | 武田薬品工業 | 高血圧 | 2016年7月 | Hiroi S, Shimasaki Y, Kikuchi T, Otsuka Y, Iwasaki K, Ohishi M. Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data. Hypertens Res. 2016 Dec;39(12):907-912. doi: 10.1038/hr.2016.96. Epub 2016 Jul 28. PMID: 27465576; PMCID: PMC5506243. |
| 論文 | 武田薬品工業 | 逆流性食道炎 | 2016年7月 | Miwa H, Takeshima T, Iwasaki K, Hiroi S. Medical cost, incidence rate, and treatment status of gastroesophageal reflux disease in Japan: analysis of claims data. J Med Econ. 2016 Nov;19(11):1049-1055. doi: 10.1080/13696998.2016.1192551. Epub 2016 Jun 1. PMID: 27207316. |
| その他 | なし | なし | 2016年6月 | Kosuke Iwasaki. Application of Agent-based Modeling (ABM) to Health Care Reform. IAAHS. ST. JOHN’S COLLOQUIUM – JUNE 2016 |
| ポスター | 武田薬品工業 | 高血圧 | 2016年5月 | Iwasaki K, Otsuka Y, Takeshima T, Nakamura Y, Shimasaki Y, Uda A, Yamabe K, Kuwabara H, Hiroi S. Using a method of indirect comparison in network meta-analysis to compare efficacy in randomized clinical trials that include patient groups with different attributes. HTAi 2016 Annual Meeting, Tokyo, Japan, May 10-14, 2016. |
| ポスター | 武田薬品工業 | なし | 2016年5月 | Hiroi S, Uda A, Tokaji A, Takeshima T, Iwasaki K. Ethical standards used in healthcare database study reports – Selected Review on High Impact Journals? HTAi 2016 Annual Meeting, Tokyo, Japan, May 10-14, 2016. |
| 論文 | 武田薬品工業 | 多発性硬化症 | 2016年5月 | Ogino M, Kawachi I, Otake K, Ohta H, Otsuka Y, Iwasaki K, Hiroi S. Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database. Clin Exp Neuroimmunol. 2016 May;7(2):158-167. doi: 10.1111/cen3.12299. Epub 2016 Mar 23. PMID: 27818711; PMCID: PMC5071668. |
| ポスター | 武田薬品工業 | ２型糖尿病 | 2016年5月 | Takeshima T, Iwasaki K, Uda A, Hiroi S, Shimasaki Y. Current status of comorbid depression among Japanese type 2 diabetes patients based on claims database analysis. ISPOR 21th Annual International Meeting, Washington DC, May 21-25, 2016. |
| ポスター | ファイザー | 喫煙 | 2015年11月 | 201509 Suwa K, Nakamura Y, Yoshikawa R, Gunji T, Iwasaki K, Igarashi A. The Association Between Smoking Cessation Outpatient Visits And Total Medical Costs: An Analysis Of Japanese Employee Based Public Health Insurance Data.Value Health. 2015 Nov;18(7):A498. |
| ポスター | なし | なし | 2015年11月 | 松山科子、小泉洋夫、岩崎宏介。エージェントベースモデルを用いた生命保険の販売戦略の検討。計測自動制御学会システム・情報部門学術講演会2015、函館市、2015年11月18－20日。 |
| その他 | アッヴィー | C型肝炎 | 2015年11月 | 岩崎宏介。Ｃ型肝炎ウイルス感染の早期発見・早期治療勧奨プロモーションの効果試算。ミリマン・レポート。2015年11月3日 |
| ポスター | 武田薬品工業 | 大腸がん | 2015年11月 | Iwasaki K, Arata H, Soeda J, Yanai T, Hiroi S. Estimation of The Progression of Colon Cancer By Japanese Large-Scale Insurance Benefits Data Analysis. ISPOR 18th Annual European Congress, Milan, Italy, Nov 7-11, 2015. |
| ポスター | なし | 多発性硬化症 | 2015年5月 | Nakamura Y. Analysis of Medical Costs of MS Relapses for MS Patients. ISPOR 20th Annual International Meeting, Philadelphia, May 16-20, 2015. |
| その他 | なし | なし | 2014年12月 | 岩崎宏介, 出井基晴, 小合徳幸。入院日数分布調査について。ミリマン・レポート。2014年12月11日 |
| 論文 | なし | なし | 2014年12月 | 岩崎宏介, 村山令二。高齢者医療の人頭払いに代わるＡＣＯ（責任医療機構：アカウンタブル・ケア・オーガナイゼーション）―オバマケア改革における医療費適正化と医療の質の向上を同時に達成する試み。社会保険旬報。No.2588(2014.12.11) |
| ポスター | なし | 高血圧 | 2014年10月 | Iwasaki K, Kogo N, Dei M. Example of Analysis Utilizing Real World Data: Medical Cost Reduction of Combination Drugs. Value Health. 2014 Nov;17(7):A720-1. doi: 10.1016/j.jval.2014.08.016. Epub 2014 Oct 26. PMID: 27202550. |
| ポスター | なし | 高血圧 | 2014年10月 | Iwasaki K, Kogo N, Dei M. Example of Analysis Utilizing Real World Data: Medical Cost Reduction by Advising Untreated-Hypertension Patients to Visit Doctors. Value Health. 2014 Nov;17(7):A760. doi: 10.1016/j.jval.2014.08.252. Epub 2014 Oct 26. PMID: 27202778. |
| 論文 | なし | なし | 2014年7月 | 岩崎宏介, 村山令二。オバマケア改革の保険加入義務づけを支える医療保険数理―民間保険者間の公平な医療費適正化競争を促すリスク調整の手法。社会保険旬報。No.2573 (2014.7.11) |
| その他 | JMDC | 高血圧 | 2014年1月 | 岩崎宏介, 出井基晴, 小合徳幸。放置高血圧者の受診勧奨の医療費削減効果 について。ミリマン・レポート。2014年1月22日 |
| 論文 | Genentech | 統合失調症 | 2014年1月 | Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits. 2014 Jan;7(1):18-26. PMID: 24991388; PMCID: PMC4031739. |
| その他 | JMDC | ２型糖尿病 | 2013年12月 | 岩崎宏介, 出井基晴, 小合徳幸。放置糖尿病者に対する受診勧告の医療費削減効果について。ミリマン・レポート。2013年12月16日 |
| 論文 | Welldoc | ２型糖尿病 | 2013年10月 | Fitch K, Pyenson BS, Iwasaki K. Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes.J Manag Care Pharm. 2013 Oct;19(8):609-20, 620a-620d. |
| 論文 | ファイザー | 市中肺炎 | 2013年9月 | Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013 Sep;6(8):494-503. |
Newsletters
A paper with Prof. Igarashi of the University of Tokyo and Shionogi Pharmaceutical Co., Ltd. has been published (February 14, 2025)
Together with Dr. Igarashi of the University of Tokyo and Shionogi Pharmaceutical Co., Ltd., we have published a new paper in a peer-reviewed journal. We will inform you for your reference.
This paper focuses on how Japanese are resistant to transmitting COVID-19 to others. Under the guidance of Professor Yoshimichi Sato, Dean of the Faculty of Humanities at Kyoto University of Advanced Science, we used the Multidimensional Empathy Scale to analyze various scales of "empathy."
Igarashi A, Kurazono K, Itsumura N, Takeshima T, Iwasaki K. Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population.
J Med Econ. 2025;28(1):260-267.
doi: 10.1080/13696998.2025.2461897.
-Overview-
Given the high infectivity of COVID-19 and the pandemic situation, the ability to prevent the use of therapeutic drugs to infect others is considered important. In addition, the evaluation of this feature is likely to vary from person to person.
In this study, we investigated the willingness to pay (WTP) for the infection prevention function of COVID-19 therapeutic drugs in Japan using an online questionnaire, and examined how much the value is, what kind of distribution it has, and what attributes affect WTP.
The original text can be downloaded from the following website.
https://www.tandfonline.com/doi/full/10.1080/13696998.2025.2461897
If you have any other comments or questions, please contact us at the address below.
Healthcare Embedded Value Accounting――Management Accounting for Health Service Evaluation and Decision-Making Support（February 3, 2025）
We would like to inform you that the above paper has been published in Social Insurance Bulletin No. 2953.
Currently, the most important challenge for health insurers in Japan is the effective and efficient management of health services.
However, current financial accounting does not map the cost and return of health services to time periods, making it difficult to capture the true outcomes of health projects. Therefore, we would like to propose "Healthcare Embedded Value Accounting (HEV Accounting)".
The HEV accounting mechanism is similar to the potential value accounting employed by life insurance companies, which consists of the insurer's net worth and the present value of future profits (the difference between the standard medical expenses if the health services were not carried out and the actual medical expenses if the health services were implemented). By comparing this to insurance business expenses, insurers can accurately understand their return on investment (ROI).
By introducing HEV accounting, insurers will be able to evaluate the effectiveness of their health services in a timely manner and effectively implement the PDCA cycle. This allows insurers to make better decisions based on detailed information that cannot be obtained through financial accounting alone.
We would like you to refer to this paper and take a new step forward in the management of your health business.
If you have any other comments or questions, please contact us at the address below.
Dr. Igarashi of the University of Tokyo, Eisai's research was presented at the Japan Society for Dementia (December 9, 2024)
Dr. Igarashi of the University of Tokyo, Dr. Matsubara and Dr. Kimura of Oita University, and Eisai Co., Ltd. presented a poster presentation at the Japan Society for Dementia Research on the following study, which predicted the demand for Lecanemab application tests through questionnaire surveys and dynamic simulations.
Milliman is involved in research design, simulation, poster creation, etc., so we will inform you for your information.
Ataru Igarashi, Noriyuki Kimura, Noriaki Ito, Chizuru Kobayashi、Kotaro Sasaki, Yukinori Sakata、Mie Azuma、Etsuro Matsubara
Willing to pay and intangible costs constituting the demand for Lecanemab application testing
The 43rd Annual Meeting of the Japan Society for Dementia November 21-23, 2024
If you have any other comments or questions, please contact us at the address below.
A paper on the impact of climate change on winter mortality has been published (December 3, 2024)
We are pleased to announce that one of our offices has published a paper on the subject on our website.
Title of the paper：The impact of climate change on winter mortality: A complex phenomenon with an uncertain future
https://www.milliman.com/en/insight/the-impact-of-climate-change-on-winter-mortality
While there have been many previous studies on the effects of heat waves on the mortality rate of climate change, the impact of low temperatures on mortality has not been fully understood. In this study, we evaluated the impact of low winter temperatures on health and mortality and developed a model to predict the future effects of climate change on the human body.
The impact of low winter temperatures on mortality can be direct due to frostbite and hypothermia, or indirect, such as an increase in cardiovascular disease, respiratory disease, and infectious diseases. To analyze this effect, in addition to the traditional Lee-Carter model, the Distributed Lag Non-Linear Model (DLNM) is used to show the mortality data and incorporate the mortality rate due to winter weather conditions into the dynamic model. DLNM is a model that takes into account the lag of a factor when the effects of a factor appear gradually over time. This lag is nonlinear, so we need to model the nonlinear shape.
If you have any comments or questions, please contact us at the address below.
Poster presentation at ISPOR Europe 2024 (November 19, 2024)
We gave the following poster presentation at ISPOR Europe 2024, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference held in Barcelona on November 17-20, 2024.
- Return on Investment of National Standardized Health Training in Japan: A Cohort Study Using “Wellness-Star☆” Health Insurance Claims Database Poster Session 4: Tuesday, 19 November 2024| 16:00 - 19:00 (Discussion Period Time: 18:00 - 19:00) In Japan, there is a system of specific health guidance along with specific health checkups, and support for lifestyle-related diseases is provided to people at risk of metabolic syndrome through behavioral change. In this study, we estimated the ROI of specific health guidance using the "Wellness Star☆" database provided by Nippon Life Insurance Company. This research is a joint research with Professor Ataru Igarashi of the University of Tokyo and members of Nippon Life Insurance Company.
- The Influence of Health Literacy on the Selection of Healthcare Facilities: An Association Between Health Literacy Level and Number of Healthcare Facilities Visited per Patient per Year Using Real World Data in Japan Poster Session 5: Wednesday, 20 November 2024|09:00 - 11:30 CET (Discussion Period Time: 09:00 - 10:00) Since health literacy is the ability to acquire, understand, and use appropriate health information, it is thought that people with high health literacy levels will choose the appropriate medical facility for each disease. In this study, we examined the relationship between health literacy and the number of medical facilities examined relative to the number of diagnosed diseases.
- Exploring the Association Between Health Literacy and Depression Prevalence Through Personal Health Record Associated With Health Insurance Claims Data Poster Session 5: Wednesday, 20 November 2024|09:00 - 11:30 CET (Discussion Period Time: 09:00 - 10:00) Productivity losses due to depression were estimated at about 0.92 trillion yen in Japan in 2005, and this amount has since expanded further. In recent years, there has been a growing awareness of the importance of health literacy, and it is expected that individuals will be able to make decisions based on information that will have an effect on health management and health improvement. In this study, we examined the relationship between health literacy and the prevalence of depression using data from DeSC Healthcare, Inc.
If you have any comments or questions, please contact us at the address below.
A paper with Shionogi was published (August 28, 2024)
Together with Dr. Shimizu of the University of Tokyo, Dr. Miyashita of Tohoku University, Dr. Saiki of Saitama Medical University, and Shionogi Pharmaceutical Co., Ltd., Milliman's Iwasaki has published a new paper in a peer-reviewed journal as a researcher at the University of Tokyo.
NDB (National Database) is a database held by the Ministry of Health, Labor and Welfare that accumulates data on medical fee statements (receipts) and specific health checkups for health insurance throughout Japan.
Yoshida M, Miyashita M, Saeki T, Hiroi S, Morioka Y, Iwasaki K, Shimizu E.
Opioid prescription status around surgery, bone metastasis, or death events among patients with breast cancer in Japan: an analysis of the Japanese public health insurance comprehensive claims database (the National Database).
Jpn J Clin Oncol. 2024 Aug 28:hyae120. doi: 10.1093/jjco/hyae120.
-Overview-
Breast cancer, which is the most common cancer in Japan women, has a relatively good prognosis and is thought to require long-term pain management, and opioids are most often used for pain management.
In this study, we used NDB to show the situation of opioid prescription for breast cancer patients in Japan as a whole, and examined differences by size, type, and region of hospitals.
The original text can be downloaded from the following website. https://academic.oup.com/jjco/advance-article/doi/10.1093/jjco/hyae120/7743189?utm_source=advanceaccess&utm_campaign=jjco&utm_medium=email
If you have any other comments or questions, please contact us at the address below.
A causal model for climate change and inflation（20th Aug 2024)
Our London office has published a paper titled “Inflation as a major climate-related risk”, so I would like to introduce the summary.
The essence of climate change is that humans have used the Earth’s resources for free. For a sustainable future, we need to stop using them for free, which will cause inflation.
However, how climate change leads to inflation is complex, and Milliman has just created a framework for a causal model. This framework is shown in Figure 1 of this paper.
Compared to the conventional frequency-severity model, the causal model has the advantages of being possible without past data, of having a good understanding of the causal mechanism, and of being able to simulate various policies.
The next step is to estimate the probability of each transition within this causal model framework. After that, validation is performed.
This paper has been published in the journal Insurance ERM. For more information, please see the website link below (registration is required to view).
https://www.insuranceerm.com/analysis/inflation-as-a-major-climate-related-risk.html
Poster presentation at ISPOR 2024 (May 23, 2024)
We gave the following poster presentation at ISPOR 2024, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference held in Atlanta on May 5-8, 2024.
- Prescription Patterns for COVID-19 before the Availability of Antiviral Drugs Using the National Database of Health Insurance Claims in Japan This study was conducted using the Ministry of Health, Labour and Welfare's national database (NDB). At the beginning of the COVID-19 epidemic, in the absence of effective therapeutic drugs, treatment with off-label prescriptions of existing drugs was considered, and it was published in guidelines by the Ministry of Health, Labour and Welfare and academic societies. These have been updated from time to time, and several drugs have since been approved for the treatment of COVID-19. In this study, we presented the actual state of drug treatment under insurance treatment since the beginning of the COVID-19 epidemic, and examined the impact of the approval status for COVID-19 and the publication in guidelines and indication approvals on actual prescriptions. https://www.ispor.org/docs/default-source/intl2024/ispor2024hsd77poster137406-pdf.pdf?sfvrsn=405f821_0
- Association between Facilities of First COVID-19 Diagnosis and Previous Outpatient Visits Based on a Claims Database Analysis This is a study using receipt data from DeSC Healthcare, Inc. During the COVID-19 epidemic, many fever patients struggled to find a place to see a doctor, and they were unable to receive medical examinations at the medical institutions they usually attended, so expectations for the family doctor system are increasing. However, the debate about the current family physician system has centered on the definition, requirements, and reimbursement of family doctors, regardless of these expectations. In this study, we examined the relationship between the medical institution where COVID-19 patients received a COVID-19 diagnosis and the medical institution they frequently visited in the past, and examined the circumstances behind the expectations of the family doctor system. https://www.ispor.org/docs/default-source/intl2024/ispor2024sa44poster137419-pdf.pdf?sfvrsn=13a06085_0 If you have any comments about this poster, please feel free to contact us.
If you have any other comments or questions, please contact us at the address below.
Paper with Novartis Pharma has been published (April 8, 2024)
For your reference, we have recently published a paper on the actual state of treatment in the ophthalmology field in a new peer-reviewed academic journal with Dr. Gomi of Hyogo University of Medicine, Dr. Kawasaki of Osaka University, Dr. Ogura of Nagoya City University, and Novartis Pharma.
Fumi Gomi, Ryo Kawasaki, Yuichiro Ogura, Kosuke Iwasaki, Tomomi Takeshima, Masafumi Yamabe, Kota Imai. Patterns of anti-vascular endothelial growth factor treatment for chorioretinal vascular diseases: Analysis of a nationwide claims database in Japan. Annals of Clinical Epidemiology 2024; 6(2):42?50 https://www.jstage.jst.go.jp/article/ace/6/2/6_24007/_html/-char/ja
Overview-
Anti-VEGF therapy is considered the first choice treatment for chorioretinal vascular diseases such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, but little research has been conducted on its treatment pattern in Japan. In this study, we used Medical Data Vision's receipt database to examine trends in the dosing interval and treatment continuation rate of anti-VEGF drugs for these diseases over a calendar year.
If you have any other comments or questions, please contact us at the address below.
[email protected]
News release from Nippon Shinyaku regarding publication of joint research paper with Milliman in an academic journal
A paper on the actual situation of anemia patients in Japan, which was a joint research with Nippon Shinyaku, was published. For your reference, a news release from Nippon Shinyaku regarding the paper has been posted on the company's website.
If you have any other comments or questions, please contact us at [email protected].
Milliman Tokyo Healthcare website has been updated.
The Milliman Tokyo Healthcare website has been updated with the following features.
- The solution has been changed to be based on past results.
- Past achievements such as published papers and poster presentations are listed in a list.
If you have any other comments or questions, please contact us at [email protected].
Contact us
We’re passionate about partnering with people to solve complex problems. Let’s chat about what’s going on with your business and how we can help.